Paper Details

  1. Home
  2. Paper Details

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

Author: BhojaniNaeem, HuttererGeorg, JeldresClaudio, KarakiewiczPierre I, OudardStéphane, PatardJean-Jacques, PatenaudeFrançois, PerrottePaul, SuardiNazareno

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Sorafenib, sunitinib, and temsirolimus, three kinase inhibitors used to treat cancer, all have a range of side effects that can be managed effectively.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To provide a systematic review of the side effects associated with sorafenib, sunitinib, and temsirolimus and to provide an outline of possible preventive or therapeutic measures. METHODS: We performed a PubMed-based systematic review of side effects associated with the three agents and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2007.11.037

データ提供：米国国立医学図書館（NLM）

Managing the Side Effects of Kinase Inhibitors in Metastatic Renal Cell Carcinoma

This study provides a comprehensive review of the side effects associated with three kinase inhibitors, sorafenib, sunitinib, and temsirolimus, used in the treatment of metastatic renal cell carcinoma (RCC). The authors discuss the frequency, severity, and management of these side effects, providing clinicians with essential information for optimizing treatment strategies. This review aims to improve the understanding and management of side effects associated with kinase inhibitor therapy for RCC patients.

Kinase Inhibitors: A Balancing Act of Efficacy and Side Effects

This review highlights the need for careful monitoring and management of side effects associated with kinase inhibitor therapy for RCC. The authors emphasize the importance of balancing the benefits of these drugs with the potential risks of adverse events. This research provides valuable guidance for clinicians managing RCC patients.

A Desert of Side Effects: Finding Solutions

Kinase inhibitors, like a powerful desert storm, can bring both relief and potential side effects. This review provides a map for navigating these side effects and maximizing the benefits of this important class of drugs.

Dr.Camel's Conclusion

Kinase inhibitors, like a powerful camel, can carry us through the desert of metastatic renal cell carcinoma, but we must be prepared for the occasional sandstorm of side effects. This review offers a guide for managing these side effects and ensuring a smoother journey.

Date :
  1. Date Completed 2008-09-11
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

18054825

DOI: Digital Object Identifier

10.1016/j.eururo.2007.11.037

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.